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Non-digestible but fermentable substrates 
(oligosaccharides). 
Adequate amounts (107) of live microorganisms. 
Examples 
• Fructans (inulin and fructo-oligosaccharides). 
• Galacto-oligosaccharides. 
• Lactulose. 
• Resistant starches and other oligosaccharides    
are under probe. 
• Bifidobacteria  (Bifidobacterium lactis). 
• Lactobacilli  (Lactobacillus lactis). 
• Streptococci  (Streptococcus thermophilus). 
Action 
Only some anaerobic bacteria (mainly 
bifidobacteria) can ferment them  importance of 
interactive consortia in human gut  (production of 
lactate by bifidobacteria  is well-exploited by 
butirate-producing bacteria). 
Multifactorial: 
• Influencing resident microbiota (replacing a missing 
part or supplementing endogenous population). 
• Only stimulating a part of the microbiota. 
Effect 
Selection of bifidobacteria and other anaerobic 
bacteria with consequent benefits to the host 
health. 
Changes in enzymatic activity, in the composition of 
the mucus secreted by colon cells, modulation of 
immune system and  sustaining the tight junctions 
(reducing the permeability of some pathogens). 
Used in a targeted way 
• Faecalibacterium prausnitzii: grows perfectly with 
fructan supplement  protection against 
Chron’s disease (anti-inflammatory effect). 
• Oxalobacter formigenes: uses oxalate for growing 
 reduces the risk of kidney stone formation. 
Microencapsulation of bacterial cells to guarantee the 
survival of the bacteria in a specific part of the 
gastrointestinal tract and an appropriate diffusion of 
metabolites and substrates. 
• Lactobacillus acidophilus: suppression of colon 
tumour incidence. 
Difficulties 
Effects of dietary modulation on the gut microbiota 
and host response are suggested to be highly 
individual. 
The effect of one probiotic strain cannot be 
extrapolated to another strain.  
 
• Firmicutes (Clostridium, Faecalibacterium, Roseburia, Ruminococcus)  
• Bacteroidetes (Bacteroides, Prevotella)                                                               Ruminococcus sp.     Clostridium sp.  
• Proteobacteria (Enterobacteriaceae)                                                             
• Fusobacteria (Fusobacterium)                         Prevotella sp.      Bacteroides sp.     
• Verrucomicrobia (Akkermansia muciniphila) 
• Cyanobacteria 
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Further research (Human Microbiome Project, MetaHIT consortiums) is needed to determine what 
exactly is a normal “healthy” gut microbiota and if positive effects are caused by the therapies or just by 
individual characteristics of the patient’s microbiota.  
Lack of knowledge in long-term complications, especially in bacteriotherapy, clinical trials and in vivo 
studies,  is retarding the progress of these therapies. 
Until remains a controversial question: is microbial variation the cause of the disease or is it just an 
effect of it? 
Establishment of stool banks and a fast standardization and regulation by FDA (Food and Drug 
Administration) would benefit the future of bacteriotherapy as the first-line therapy for CDI. 
FUTURE: Synthetic stool (knowing the exact bacterial composition) against antibiotic resistant CD colitis 
(↓ Proteobacteria, followed by gradually    in Bacteroidetes, Firmicutes and Verrucomicrobia phyla). 
Figure 2. Representation of a human gut. On the left side 
are detailed the seven phyla that should be present in the 
yet undescribed “healthy” microbiota. 
Figure 1. Mice cecal bacteria with rich (left) and poor (right) bacterial 
populations (RIKEN; Institute of scientific research, Japan). 
Firmicutes and Bacteroidetes are the 
only dominant phyla 
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There are different ways of instilling stool samples 
Higher cure rates in C. difficile infection (CDI) by colonoscopic route 
(93,2%) than by nasogastric one (85,3%) in Pinn et al. review. 
Donor selection based on  
Medical history : 
- Users of illicit drugs, taking antibiotics within preceding 3 months 
or people with Diabetes Mellitus or Metabolic Syndrome, among 
others, are excluded from being donors. 
Laboratory testing: 
- Hepatitis viruses and Abs against them, HIV and stool culture. 
- Different Ag/Ab tests: Cryptosporidium, Giardia, Helicobacter pylori 
and Rotavirus. 
- Detection of Cyclospora and Isospora (acid fast stain). 
- Stool ova and parasites exam. 
First-degree or closer relatives: genetically similarities would 
represent a great number of microbial species in common. 
Pro: CDI cure rate is higher using bacteriotherapy than only using 
vancomycin or metronidazole (apart from avoiding resistance 
problems). 
Con: Safety  unanswered questions about long-term complications. 
Balanced gut microbiota (Homeostasis) 
Beneficial/Commensal >> Opportunistic/Pathogens 
Unbalanced gut microbiota (Dysbiosis) 
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Dysbiosis-associated diseases  
Inflammatory Bowel Disease, colorectal cancer, 
obesity, Clostridium difficile colitis, Chron’s disease… 
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 Up to 1014 bacteria can be found in the gut (the largest bacterial population in the body).  
 These have multiple functions related to the fermentation of residual foods, modulation of immune response and protection against opportunistic pathogens.  
 It is believed that a more diverse microbiota is correlated to a “healthy” person whereas a lower one can bring to a disruption of the homeostasis state.  
 An alteration of the gut microbiota has been associated with a phenomenon of “dysbacteriosis” (dysbiosis), which can be accompanied by multiple associated pathologies. 
 
 INTRODUCTION 
Figure  3. Representation 
of a balanced microbiota. 
Figure  4. Representation 
of  a less equitable 
microbiota. 
Figure  5. Representation 
of an overgrowth of one 
bacterial population. 
